Dechra Animal Health has launched Revozyn RTU, billed as a revolutionary breakthrough for subclinical and clinical local mastitis in cows.

Revozyn RTU, which contains 400 mg/ml Penethamate hydriodide, is the first ready-to-use injectable narrow spectrum Penethamate on the UK market. It can also be used to treat relapses of old infections.

Dechra says that the intramuscular injection works by diffusing through the blood vessels and accumulating in the udder tissue and milk, treating the whole udder effectively. Apparently the new formulation also features an ion trapping mechanism that results in high Benzylpenicillin concentration in milk and udder tissue.

Revozyn RTU comes in a 50ml multi dose vial. It has a 28-day shelf life after first use and has withdrawal periods of four days for milk and 10 days for meat and offal.

Dechra Brand Manager Emma Jennings said: "The treatment and control of mastitis is one of the largest costs to any dairy farmer. It affects productivity and cow welfare and we are delighted to be able to introduce this revolutionary product.

"Revozyn RTU can change the way that clinical and subclinical mastitis in dairy cattle is treated. Its narrow spectrum of activity means that the risk of antibiotic resistance is reduced and there is no need for additional animal handling, thereby saving time and protecting user safety.

“The flexible dosing of Revozyn RTU and 28-day shelf life also make it a cost effective option for farmers".

For more information, visit www.dechra.co.uk.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.